Integrated Filing — IndAS



General information about company
Scrip Code 509079
NSE Symbol GUFICBIO
MSEI Symbol NOTLISTED
ISIN INE742B01025
Name of company GUFIC BIOSCIENCES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 30-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment The Company's business activity falls within a single operating segment i.e. Pharmaceuticals
Start date and time of board meeting 30-May-2025   17:00:00
End date and time of board meeting 30-May-2025   18:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2024-12-27
Indicate Company website link for updated RPT policy of the Company http://gufic.com/wp-content/uploads/2024/12/Related%20party%20transactions%20policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The Company has not defaulted in payment of interest/ instalment obligations on loans from Banks and Financial Institutions. Further, the Company does not have any outstanding debt securities (including Commercial Paper), Medium Term Notes (MTNs), Foreign Currency Convertible Bonds (FCCBs), External Commercial Borrowings (ECBs), etc.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2050201000 8198059000
Other income 3830000 36150000
Total income 2054031000 8234209000
2 Expenses
(a) Cost of materials consumed 1229124000 3442010000
(b) Purchases of stock-in-trade 108489000 554143000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -440937000 -249142000
(d) Employee benefit expense 355745000 1270506000
(e) Finance costs 83998000 231116000
(f) Depreciation, depletion and amortisation expense 78433000 210644000
(f) Other Expenses
1 Other Expenses 531386000 1830657000
Total other expenses 531386000 1830657000
Total expenses 1946238000 7289934000
3 Total profit before exceptional items and tax 107793000 944275000
4 Exceptional items 0 0
5 Total profit before tax 107793000 944275000
6 Tax expense
7 Current tax 2934000 187434000
8 Deferred tax 25118000 57513000
9 Total tax expenses 28052000 244947000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 79741000 699328000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 79741000 699328000
17 Other comprehensive income net of taxes -1277000 -1277000
18 Total Comprehensive Income for the period 78464000 698051000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 100278000 100278000
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 5913351000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.8 6.97
Diluted earnings (loss) per share from continuing operations 0.8 6.97
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.8 6.97
Diluted earnings (loss) per share from continuing and discontinued operations 0.8 6.97
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1. The above financial results have been prepared in accordance with the Companies Indian Accounting Standards Rules 2015 as amended prescribed under section 133 of Companies Act 2013 read with rules issued thereunder. n n2. The above results for the quarter and year ended March 31 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 30 2025. The Statutory Auditors have carried out audit of the results for quarter and year ended March 31 2025. n n3. The Companys business activity falls within a single operating segment i.e. Pharmaceuticals. n n4. The Board of Directors at its meeting held on May 30 2025 has recommended a final dividend of Re. 0.10 per equity share i.e. at the rate 10 percent on the face value of Re. 1 each for the financial year 2024 25 subject to the approval of the shareholders at the ensuing Annual General Meeting. n n5. The Company has incorporated Gufic UK Limited GUL in United Kingdom on March 15 2022 Gufic Ireland Limited GIL in Ireland on March 02 2023 Veira Life FZE VLF in Dubai UAE on March 25 2024 and Gufic Prime Private Limited GPPL in India on November 18 2023 with the intention of making GUL GIL and VLF its Wholly Owned Subsidiaries and GPPL as its Subsidiary Company. As of March 31 2025 neither investment have been made in GIL nor they have begun its business operations. Consequently there was no need to consolidate the accounts of GIL with the Company. However the Company has invested in GUL on September 13 2023 GPPL on April 25 2024 and VLF on January 13 2025 by subscribing to its shares. Consequently the consolidated financial results for the quarter and financial year ended March 31 2025 have been prepared by the Company considering the financials of GUL GPPL and VLF. n n6. The equity shares and basic diluted earnings per share has been presented in accordance with Ind AS 33 Earning per share. n n7. The figures for the quarter ended March 31 2025 and March 31 2024 are balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter ended December 31 2024 and December 31 2023 respectively which were subjected to limited review. n n8. Previous year or quarters figures have been regrouped or reclassified wherever necessary. n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 4996480000
Capital work-in-progress 218163000
Investment property 0
Goodwill 0
Other intangible assets 63423000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 28095000
Trade receivables, non-current 0
Loans, non-current 2158000
Other non-current financial assets 97263000
Total non-current financial assets 127516000
Deferred tax assets (net) 0
Other non-current assets 52917000
Total non-current assets 5458499000
2 Current assets
Inventories 2168690000
Current financial asset
Current investments 0
Trade receivables, current 3146069000
Cash and cash equivalents 149088000
Bank balance other than cash and cash equivalents 132989000
Loans, current 3219000
Other current financial assets 622004000
Total current financial assets 4053369000
Current tax assets (net) 15705000
Other current assets 0
Total current assets 6237764000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 11696263000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 100278000
Other equity 5913351000
Total equity attributable to owners of parent 6013629000
Non controlling interest
Total equity 6013629000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1304996000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 249669000
Total non-current financial liabilities 1554665000
Provisions, non-current 174916000
Deferred tax liabilities (net) 77716000
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 1807297000
Current liabilities
Current financial liabilities
Borrowings, current 1798750000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 22207000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1565288000
Total Trade payable 1587495000
Other current financial liabilities 214154000
Total current financial liabilities 3600399000
Other current liabilities 231129000
Provisions, current 43809000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 3875337000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 5682634000
Total equity and liabilites 11696263000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to Profit or Loss -1706000 -1706000
Total Amount of items that will not be reclassified to profit and loss -1706000 -1706000
2 Income tax relating to items that will not be reclassified to profit or loss -429000 -429000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income -1277000 -1277000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 944275000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 231116000
Adjustments for decrease (increase) in inventories -163869000
Adjustments for decrease (increase) in trade receivables, current 73110000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 0
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 165490000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 210644000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 5709000
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 14820000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 4240000
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 511620000
Net cash flows from (used in) operations 1455895000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 228118000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 1227777000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 10148000
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 47669000
Purchase of property, plant and equipment 755234000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 9318000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -9517000
Net cash flows from (used in) investing activities -717912000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 168036000
Repayments of borrowings 235468000
Payments of lease liabilities 85800000
Dividends paid 10028000
Interest paid 208781000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -372041000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 137824000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 137824000
Cash and cash equivalents cash flow statement at beginning of period 11264000
Cash and cash equivalents cash flow statement at end of period 149088000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Mittal Agarwal & Company, Chartered Accountants Yes 30-Apr-2028


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Gufic Biosciences Limited Gufic Private Limited Enterprise over which Key Managerial Personnel are able to exercise significant influence Any other transaction Receiving of services 4500000 Approved 3640000 0 0
2 Gufic Biosciences Limited Gufic Private Limited Enterprise over which Key Managerial Personnel are able to exercise significant influence Any other transaction Reimbursement of expenses paid 500000 Approved 156000 0 0
3 Gufic Biosciences Limited Gufic Private Limited Enterprise over which Key Managerial Personnel are able to exercise significant influence Any other transaction Lease Rental paid 42000000 Approved 21000000 0 0
4 Gufic Biosciences Limited Gufic Private Limited Enterprise over which Key Managerial Personnel are able to exercise significant influence Any other transaction Interest Free Security Deposit given against Lease - 0 35000000 35000000
5 Gufic Biosciences Limited Gufic Chem Private Limited Enterprise over which Key Managerial Personnel are able to exercise significant influence Any other transaction Lease Rental paid 4800000 Approved 2400000 -3976000 0
6 Gufic Biosciences Limited Gufic Chem Private Limited Enterprise over which Key Managerial Personnel are able to exercise significant influence Any other transaction Interest Free Security Deposit given against Lease - 0 3600000 3600000
7 Gufic Biosciences Limited Tricon Enterprises Private Limited Enterprise over which Key Managerial Personnel are able to exercise significant influence Sale of goods or services 5000000 Approved 1015000 401000 804000
8 Gufic Biosciences Limited Gufic UK Limited Wholly Owned Subsidiary of the Company Investment - 0 5412000 5412000
9 Gufic Biosciences Limited Gufic Prime Private Limited Subsidiary of the Company Investment - 0 88000 88000
10 Gufic Biosciences Limited Veira Life FZE Wholly Owned Subsidiary of the Company Investment - 4752000 0 4752000
11 Gufic Biosciences Limited Mr. Jayesh P. Choksi Promoter, Chairman & Managing Director Remuneration Approval of Audit Committee is not required 7011000 0 0
12 Gufic Biosciences Limited Mr. Jayesh P. Choksi Promoter, Chairman & Managing Director Any other transaction Perquisites Approval of Audit Committee is not required 20000 0 0
13 Gufic Biosciences Limited Mr. Pranav J Choksi Promoter, Chief Executive Officer & Whole Time Director Remuneration Approval of Audit Committee is not required 5124000 0 0
14 Gufic Biosciences Limited Mr. Pranav J Choksi Promoter, Chief Executive Officer & Whole Time Director Any other transaction Perquisites Approval of Audit Committee is not required 20000 0 0
15 Gufic Biosciences Limited Mrs. Pooja P. Choksi Immediate Relative of Key Managerial Personnel Any other transaction Receiving of services 950000 Approved 475000 -71000 -71000
16 Gufic Biosciences Limited Mr. Pankaj J Gandhi Whole Time Director Remuneration Approval of Audit Committee is not required 1071000 0 0
17 Gufic Biosciences Limited Mr. Pankaj J Gandhi Whole Time Director Any other transaction Reimbursement of expenses paid Approval of Audit Committee is not required 1311000 98000 -46000
18 Gufic Biosciences Limited Mr. Gopal M Daptari Independent Director (Upto 23.11.2024) Any other transaction Sitting fees Approval of Audit Committee is not required 80000 -36000 0
19 Gufic Biosciences Limited Mr. Shreyas K Patel Independent Director (Upto 25.09.2024) Any other transaction Sitting fees Approval of Audit Committee is not required 35000 0 0
20 Gufic Biosciences Limited Dr. Anu Aurora Independent Director Any other transaction Sitting fees Approval of Audit Committee is not required 135000 0 0
21 Gufic Biosciences Limited Mr. Kamal Kishore Seth Independent Director Any other transaction Sitting fees Approval of Audit Committee is not required 150000 0 0
22 Gufic Biosciences Limited Mr. Akshya Kumar Mahapatra Independent Director (Appointed w.e.f 14.11.2024) Any other transaction Sitting fees Approval of Audit Committee is not required 105000 0 0
23 Gufic Biosciences Limited Veira Life FZE Wholly Owned Subsidiary of the Company Any other transaction Reimbursement of expenses received 2500000 Approved 2259000 0 2259000
Total value of transaction during the reporting period 50759000